Study of golidocitinib for immune thrombocytopenia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a new daily pill called golidocitinib for adults with immune thrombocytopenia (ITP) — a condition where the immune system attacks platelets, leading to low counts and bleeding risk. The drug aims to lower that immune attack and raise platelet counts, and may help people who have not had lasting success with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have had primary ITP for more than 3 months.
- Your platelet counts have been below 30,000 per microliter on at least two tests taken a week or more apart.
- Your ITP has not responded well to or has come back after at least two previous treatments, including steroids.
- You have had some response to treatment in the past.
- You are willing to use contraception during the study if needed (for women who could become pregnant and men).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called DZD8586 for people with long-term ITP (low platelets) that hasn't improved with standard treatments. The goal is to see if it can safely raise platelet counts and reduce bleeding risk.
This trial tests an investigational drug called CID-103 for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. It aims to find the right dose and see if it can safely increase platelet counts to reduce bleeding risk.
This trial tests the combination of upadacitinib (an immune-modulating drug) and high-dose dexamethasone (a steroid) as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). The goal is to see if this combination can raise your platelet count and reduce bleeding better than usual care.
This trial tests if a substance called NAD can help adults with immune thrombocytopenia (ITP) whose platelet levels stay low even after standard treatments. ITP is a condition where the immune system attacks platelets, causing easy bruising and bleeding. The study aims to see if NAD can safely raise platelet counts.
This study tests an investigational pill (golidocitinib) for people whose interstitial lung disease is getting worse quickly, despite needing steroids. The goal is to see if this drug can help slow or stop the rapid decline in lung function.
This study tests whether adding another medicine (telitacicept) to a standard platelet-boosting drug (eltrombopag) works better than eltrombopag alone for adults with ITP that hasn't improved with steroids. The goal is to help raise your platelet counts and reduce bleeding risk.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.